PRESENTATION

Q4 2022 — Results presentation

Q4 2022PDF · 40 pages4.4 MB


-- 1 of 40 --

4th Quarter 2022
Earnings Call
January 24, 2023

-- 2 of 40 --

Cautionary Note on Forward-looking Statements
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial
performance, product development, market position and business strategy, and the anticipated separation of the Company’s Consumer Health business. The viewer is cautioned not to rely on
these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties
materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as
interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product
research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the
impact of patent expirations; the ability of the company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally
or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability
claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of
purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government
agencies; the Company’s ability to satisfy the necessary conditions to consummate the separation of the Company’s Consumer Health business on a timely basis or at all; the Company’s ability to
successfully separate the Company’s Consumer Health business and realize the anticipated benefits from the separation; the New Consumer Health Company’s ability to succeed as a standalone
publicly traded company; and risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures
implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the company’s ability to execute business
continuity plans, as a result of the COVID-19 pandemic. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form
10-K for the fiscal year ended January 2, 2022, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson &
Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or
on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update
any forward-looking statement as a result of new information or future events or developments.
Cautionary Note on Non-GAAP Financial Measures
This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release
and the Investor Relations section of the Company’s website at www.investor.jnj.com/sales-earnings.cfm.
3

-- 3 of 40 --

Immunology REMICADE and SIMPONI/ SIMPONI ARIA marketing partners are Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA
discovered using MorphoSys AG antibody technology
Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL
CONSTA developed in collaboration with Alkermes, Inc.
Infectious Diseases
PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with
ViiV Healthcare UK. Research and development activities for the Company’s COVID-19 vaccine, including the ENSEMBLE clinical trial and the delivery of doses for the U.S., have been funded in
part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development
Authority (BARDA), under Contract No. HHSO100201700018C, and in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)
at the U.S. Department of Health and Human Services (HHS)
Cardiovascular/
Metabolism/Other
INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG;
PROCRIT/ EPREX licensed from Amgen Inc., and X-Linked Retinitis Pigmentosa: AAV-RPGR licensed from MeiraGTx
Oncology
IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in
collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S, BALVERSA licensed and discovered in collaboration with Astex
Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; cilta-cel licensed and developed in collaboration with Legend Biotech USA Inc. and Legend
Biotech Ireland Limited, niraparib licensed from TESARO, Inc., an oncology-focused business within GSK, lazertinib licensed from Yuhan Corporation, DuoBody platform licensed from Genmab A/S
relates to several bispecific antibody programs, ENHANZE platform licensed from Halozyme Therapeutics, Inc.
Pulmonary Hypertension 	UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan
Global Public Health
Janssen’s Monovalent Ebola Vaccine is developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S. The program has benefited from funding and
preclinical services from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, NIAID support included 2 product development contracts starting in 2008 and 8 pre-clinical
services contracts. This program is also receiving funding from the IMI2 Joint Undertaking under EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN
(grant nr. 115850) and EBODAC (grant nr. 115847). The IMI2 Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation program and the European
Federation of Pharmaceutical Industries and Associations (EFPIA). Further funding for the Ebola vaccine regimen has been provided by BARDA, within the U.S. Department of Health and Human
Services’ Office of the Assistant Secretary for Preparedness and Response, under Contract Numbers HHSO100201700013C and HHSO100201500008C. The initial work on Ebola was conducted
which was extended from 2002 until 2011. 2002 and 2007 via a Cooperative Research and Development Agreement (CRADA is AI-0114) between Janssen/Crucell and the Vaccine Research Center
(VRC)/NIAID, part of the NIH. Janssen/Crucell have licenses to much of VRC’s Ebola IP specific for human adenovirus under the Ad26/Ad35 Ebola vaccine CRADA invention. VAC69120 (Filovirus
multivalent vaccine) developed in collaboration with Bavarian Nordic; funding: NIH Division of Microbiology and Infectious Diseases (DMID), under Contract Number HHSN272200800056C.
Strategic Partnerships,
Collaborations & Licensing Arrangements
4
During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or
licensed from other companies. The following is an acknowledgement of those relationships:

-- 4 of 40 --

5
Agenda
CEO Remarks
Enterprise Highlights
Sales Performance and Earnings Review
Capital Allocation and Guidance
Q&A
1
2
3
4
5
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Jessica Moore
Vice President,
Investor Relations
Joaquin Duato
Chairman of the Board and
Chief Executive Officer

-- 5 of 40 --

Joaquin Duato
Chairman of the Board and Chief
Executive Officer

-- 6 of 40 --

7

-- 7 of 40 --



-- 8 of 40 --

9

-- 9 of 40 --



-- 10 of 40 --



-- 11 of 40 --

12

-- 12 of 40 --



-- 13 of 40 --

14

-- 14 of 40 --

15

-- 15 of 40 --

16

-- 16 of 40 --

Jessica Moore
Vice President,
Investor Relations

-- 17 of 40 --

Regional Sales Results 	Q4 2022 	Q4 2021
% CHANGE
Reported 	Operational1
U.S. 	$12.5 	$12.2 	2.9% 	2.9%
Europe 	5.8 	6.9 	(16.0) 	(6.3)
Western Hemisphere
(ex U.S.) 1.5 	1.5 	5.9 	11.8
Asia-Pacific, Africa 	3.8 	4.3 	(10.0) 	3.1
International 	11.2 	12.6 	(11.5) 	(1.1)
Worldwide (WW) 	$23.7 	$24.8 	(4.4)% 	0.9%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
4th Quarter 2022 Sales
Dollars in Billions
18

-- 18 of 40 --

10.3%; 15.5% 1
Q4 2022 	Q4 2021
$2.35
$2.13
4th Quarter 2022 Financial Highlights
Dollars in Billions, except EPS
Reported %; Operational % 1
19
Sales
Adjusted Earnings 2 Adjusted EPS2
(4.4)%; 0.9% 1
GAAP Earnings
(25.7)%
$3.5
$4.7
9.5%
Q4 2022 	Q4 2021
GAAP EPS
(24.9)%
$1.33
$1.77
Q4 2022	Q4 2022 	Q4 2021 	Q4 2021	Q4 2022 	Q4 2021
$6.2
$5.7
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website
$23.7 $24.8

-- 19 of 40 --

Regional Sales Results 	2022 	2021
% CHANGE
Reported 	Operational1
U.S. 	$48.6 	$47.2 	3.0% 	3.0%
Europe 	23.4 	23.6 	(0.6) 	11.0
Western Hemisphere
(ex U.S.) 6.1 	5.8 	6.5 	10.2
Asia-Pacific, Africa 	16.8 	17.3 	(2.8) 	6.2
International 	46.4 	46.6 	(0.6) 	9.1
Worldwide (WW) 	$94.9 	$93.8 	1.3% 	6.1%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding
Full Year 2022 Sales
Dollars in Billions
20

-- 20 of 40 --

3.6%; 9.2% 1
2022 	2021
$10.15 $9.80
Full Year 2022 Financial Highlights
Dollars in Billions, except EPS
Reported %; Operational % 1
21
Sales
Adjusted Earnings 2 Adjusted EPS2
1.3%; 6.1% 1
$94.9 	$93.8
GAAP Earnings
(14.1)%
$17.9
$20.9
3.2%
2022 	2021
GAAP EPS
(13.8)%
$6.73
$7.81
2022	2022 	2021 	2021	2022 	2021
$27.0 	$26.2
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website

-- 21 of 40 --

OTC
$1,569
Skin Health/Beauty
$1,088
Oral Care
$370
Baby Care
$356
Women's Health
$220
Wound Care/Other
$163
$3,767
1.0%, 6.4%
WW Sales $MM
■ Reported Growth 	■ Operational Growth 1
Consumer Health Highlights – 4th Quarter 2022
Operational growth 1 driven by OTC and U.S. Skin Health / Beauty
22
Key Drivers of Operational Performance1,3
OTC3 	• 	Growth driven by price actions primarily in the U.S., increased Cough/Cold/Flu adult
and pediatric incidences, and category recovery, partially offset by supply constraints
Skin
Health/
Beauty
• 	Growth driven by price actions, lapping prior year higher-level of supply constraints,
and NEUTROGENA strength in club and e-commerce channels, partially offset by
U.S. portfolio simplification, negative impacts of COVID-19 in China, and suspension
of personal care sales in Russia
Oral Care • 	Decline driven by category decline, competitive pressures in EMEA and China, and
negative impacts of COVID-19 in China, partially offset by price actions
Baby Care • 	Decline driven by weakness in India, negative impacts of COVID-19 in China, and
suspension of personal care sales in Russia, partially offset by price actions
Women’s
Health • 	Growth driven by price actions and continued strong performance in India
Wound
Care/Other • 	Growth driven by price actions and supply recovery
Adjusted Operational Sales2,3: WW 6.4%, U.S. 11.0%, Int’l 3.2%
Reported 3: 	WW 1.0%, U.S. 10.9%, Int’l (5.8)%
Operational1,3: WW 6.4%, U.S. 10.9%, Int’l 3.2%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes; Note: Values may not add due to rounding
8.6%, 13.7%
(5.5)%, 4.6%
(0.5)%, 3.1%
(10.6)%, (5.0)%
(8.4)%, (3.7)%
0.4%, 5.4%
3

-- 22 of 40 --

Key Drivers of Operational Performance1,3
Immunology
• 	STELARA increase driven by market and share growth in both CD and UC, as
well as a favorable PPA, partially offset by unfavorable patient mix, increased
rebates, timing of shipments in ASPAC, and austerity measures in Europe
• 	Strength in TREMFYA due to share gains in both PsO and PsA and market
growth, partially offset by an unfavorable PPA, patient mix, and rebates
• 	REMICADE decline due to biosimilar competition
Infectious Diseases 3 	• 	Decline driven by the COVID-19 Vaccine and increased OUS competition for
PREZISTA/PREZCOBIX/REZOLSTA
Neuroscience 3
• 	Paliperidone long-acting injectables growth due to strength of INVEGA
SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA driven by new patient
starts and persistency, and launch of INVEGA HAFYERA, partially offset by
unfavorable patient mix, PPAs, and the loss of exclusivity in EU
Oncology
• 	DARZALEX increase driven by share gains in all regions, continued strong market
growth, and uptake of the subcutaneous formulation
• 	Continued strong share gains and market growth for ERLEADA
• 	Growth partially offset by ZYTIGA loss of exclusivity in EU
• 	IMBRUVICA decline due to global competitive pressures and a suppressed CLL
market, but maintains its market leadership position
Cardiovascular/
Metabolism/
Other (CVM/Other)3
• 	XARELTO increase due to volume growth and share gains, partially offset by
patient mix and rebating
• 	INVOKANA/INVOKAMET decline due to continued competitive pressures and
increased utilization of government channels
Pulmonary
Hypertension (PH)
• 	Increase driven by strong market growth and share gains from UPTRAVI and
OPSUMIT, despite COVID-19 related pressures
• 	Continued declines in Other Pulmonary Hypertension
Adjusted Operational Sales2,3: WW (2.3)%, U.S. (0.4)%, Int’l (4.4)%
Immunology
$4,118
Infectious Diseases
$1,540
Neuroscience
$1,737
Oncology
$3,927
CVM/Other
$971
PH
$870	$13,163
(7.4)%, (2.5)%
WW Sales $MM
■ Reported Growth 	■ Operational Growth 1
Pharmaceutical Highlights – 4th Quarter 2022
23
Reported 3: 	WW (7.4)%, U.S. (0.6)%, Int’l (14.9)%
Operational1,3: WW (2.5)%, U.S. (0.6)%, Int’l (4.5)%
(4.2)%, (2.4)%
2.3%, 6.9%
3.9%, 10.9%
(2.8)%, 2.4%
(36.6)%, (31.4)%
(5.4)%, (1.8)%
Excluding COVID-19 Vaccine, solid operational growth 1 driven by key brands
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes; Note: Values may not add due to rounding
3
3
3

-- 23 of 40 --

Orthopaedics
$2,148
Surgery
$2,384
Vision
$1,145
Interventional
Solutions
$1,098
$6,776
(1.2)%, 4.9%
WW Sales $MM
■ Reported Growth 	■ Operational Growth 1
MedTech Highlights – 4th Quarter 2022
Operational growth 1 driven by market recovery and innovation partially offset by impacts in China
24
Reported: 	WW (1.2)%, U.S. 7.1%, Int’l (8.6)%
Operational1: 	WW 4.9%, U.S. 7.1%, Int’l 2.9%
Key Drivers of Operational Performance1
Interventional
Solutions
• 	Electrophysiology: Double digit increase driven by market growth, new product performance (OCTARAY, QDOT and
VIZIGO), and commercial execution, partially offset by COVID-19 related procedure disruption in China
• 	Abiomed: Includes sales as of December 22, 2022
Orthopaedics
• 	Hips: Growth (~ +10% U.S. / ~ +6% WW) reflects continued procedure recovery and strength across the portfolio
(ACTIS Stem and PINNACLE Dual Mobility with pull through enabled by KINCISE & VELYS Hip Navigation) partially
offset by impacts of volume-based procurement and COVID-19 related procedure disruption in China
• 	Trauma: Growth primarily driven by uptake of recently launched products (Advanced Nailing Systems, VA Clavicle)
partially offset by softer procedure volumes in the U.S. and impacts of volume-based procurement and COVID-19
related procedure disruption in China
• 	Knees: Growth (~ +12% U.S. / ~ +8% WW) driven primarily by procedure recovery, strength of the ATTUNE portfolio
and pull through related to the VELYS Robotic assisted solution, partially offset by impacts of volume-based
procurement and COVID-19 related procedure disruption in China and timing of OUS tenders
• 	Spine, Sports & Other: Growth reflects market recovery and benefit from new products (VELYS Digital Solutions,
INHANCE, SYMPHONY), partially offset by impacts of volume-based procurement and COVID-19 related procedure
disruption in China and competitive pressures in Spine
• 	Spine: WW: ~ -6%, U.S.: ~ +2%, OUS ~ -17%
Surgery
• 	Advanced:
• 	Endocutters: ~ -1% Primarily due to impacts of volume-based procurement and COVID-19 related procedure
disruption in China as well as stocking reductions and competitive pressures predominately in the U.S. Decline was
partially offset by market recovery and strength of new products OUS and a benefit from a reclass from General
Surgery (~+110 bps).
• 	Biosurgery: ~ +2% Reflects benefits from new products (SURGIFLO, SURGICEL Powder and VISTASEAL)
partially offset by strong U.S. market demand in the prior year for infection prevention products and COVID-19
related procedure disruption in China
• 	Energy: ~ Flat driven by strength of new products (ENSEAL X1, HD1000i) coupled with competitive supply
challenges, offset by impacts of volume-based procurement and COVID-19 related procedure disruption in China
• 	General: Growth driven primarily by market recovery coupled with technology penetration (Barbed & PLUS Sutures)
Vision
• 	Contact Lenses/Other: Growth driven by strong performance in the ACUVUE OASYS 1-Day family (including recent
launches of OASYS MAX 1-day and OASYS Multifocal), price actions, and effective commercial execution, partially
offset by supply challenges
• 	Surgical: Decline reflects comparisons to strong prior year Refractive market and supply challenges, partially offset by
strong demand for TECNIS portfolio (including recently launched products TECNIS Eyhance and TECNIS Synergy)
Adjusted Operational Sales 2: WW 4.4%, U.S. 5.9%, Int’l 3.0%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding; The MedTech segment was previously referred to as the Medical Devices segment
7.8%, 15.1%
(2.2)%, 4.8%
(0.4)%, 4.0%
(5.1)%, 1.4%

-- 24 of 40 --

2022 	2021 	%
Increase
(Decrease)	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$23,706 	100.0 	$24,804 	100.0 	(4.4)
Cost of products sold 	7,765 	32.8 	7,955 	32.1 	(2.4)
Gross Profit 	15,941 	67.2 	16,849 	67.9 	(5.4)
Selling, marketing and administrative expenses 	6,512 	27.4 	7,154 	28.9 	(9.0)
Research and development expense 	3,841 	16.2 	4,720 	19.0 	(18.6)
In-process research and development 	173 	0.7 	0 	0.0
Interest (income) expense, net 	(77) 	(0.3) 	47 	0.2
Other (income) expense, net 	1,207 	5.1 	9 	0.0
Restructuring 	84 	0.4 	83 	0.3
Earnings before provision for taxes on income 	4,201 	17.7 	4,836 	19.5 	(13.1)
Provision for taxes on income 	681 	2.9 	100 	0.4 	581.0
Net Earnings 	$3,520 	14.8 	$4,736 	19.1 	(25.7)
-
Net earnings per share (Diluted) 	$1.33 	$1.77 	(24.9)
Average shares outstanding (Diluted) 	2,650.1 	2,670.2
Effective tax rate 	16.2% 	2.1%
.
Adjusted earnings before provision for taxes and net earnings1
Earnings before provision for taxes on income 	$7,418 	31.3 	$6,339 	25.6 	17.0
Net earnings 	$6,218 	26.2 	$5,678 	22.9 	9.5
Net earnings per share (Diluted) 	$2.35 	$2.13 	10.3
Effective tax rate 	16.2% 	10.4%
Condensed Consolidated Statement of Earnings
1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 	25
4 th Quarter 2022
(Unaudited; Dollar and Shares in Millions Except Per Share Figures)

-- 25 of 40 --

2022 	2021
Adjusted Income Before Tax by Segment1
4 th Quarter 2022
26
Pharmaceutical
MedTech
Consumer Health
Expenses Not Allocated to Segments
Q4 2022 	Q4 2021
Pharmaceutical 3 38.2% 	33.9%
MedTech 	25.3% 	18.1%
Consumer Health 3 22.0% 	18.6%
Total 	31.3% 	25.6%
% to Sales
1 	Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website
2 	Estimated as of 1/24/2023
3 	Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes
Note: Values may not add due to rounding
($0.2) 	($0.4)
$6.3B
$4.8
$1.2
$0.7
$7.4B
$5.0
$1.7
$0.8
2

-- 26 of 40 --

Joseph J. Wolk
Executive Vice President,
Chief Financial Officer

-- 27 of 40 --

Notable Announcements in 4th Quarter 2022
1
Pharmaceutical
• 	Regulatory:
– 	U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory
Multiple Myeloma
– 	Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
• 	Data Release:
– 	New TREMFYA (guselkumab) Data Shows an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with
Moderately to Severely Active Ulcerative Colitis
– 	Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and
Distinguished Portfolio
– 	Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for
Patients with Difficult-to-Control Hypertension
– 	New TREMFYA (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in
Health-Related Quality of Life
– 	New TREMFYA (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse
Active Psoriatic Arthritis Patient Population
MedTech
• 	Regulatory:
– 	DePuy Synthes Receives FDA Clearance for TELIGEN System
• 	Data Release:
– 	CERENOVUS Reveals Positive Outcomes with Thrombectomy in Global Registry Studying Stroke-Inducing Blood Clots
Enterprise
– 	Johnson & Johnson Names CEO Joaquin Duato as Chairman of the Board
– 	Johnson & Johnson Completes Acquisition of Abiomed
28	1 These developments and all other news releases are available on the company’s website at news releases or JNJ.com news releases, as well as www.factsabouttalc.com, www.factsaboutourprescriptionopioids.com, and www.LTLManagementInformation.com

-- 28 of 40 --

Capital Allocation Strategy
Capital Allocation
Organic growth business needs
Free cash flow1
Priorities are clear and remain unchanged
Competitive dividends
Share repurchases
HIGHER
PRIORITY
LOWER
PRIORITY
Investment in M&A
Dollars in Billions 	Q4 2022
Cash and Marketable
Securities $24
Debt 	($40)
Net Debt 	($16)
Free Cash Flow1,2 ~$17
Full Year 2022:
$14.6B invested in R&D
$11.7B in dividends paid
to shareholders
Note: values may have been rounded
1 Non-GAAP measure; cash flow from operations less CAPEX
2 Estimated as of January 24, 2023. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings
3 Announced $5B share repurchase program on September 14, 2022 29
Note: values may have been rounded
$2.5B in share repurchases;
~50% of the program completed 3

-- 29 of 40 --

1 Non-GAAP measure; excludes acquisitions and divestitures 	4 Non-GAAP measure; excludes intangible amortization expense and special items
2 Non-GAAP measure; excludes the impact of translational currency 	5 Sales less: COGS, SM&A and R&D expenses
3 Euro Average Rate: January 2023 = $1.08 	6 Excludes COVID-19 Vaccine
Note: Percentages may be rounded 	30
2023 P&L Guidance
January 	Comments
Adjusted Operational Sales1,2,6 	3.5% - 4.5% 	Midpoint of 4.0%
Operational Sales2,6 	$96.9B - $97.9B
4.5% – 5.5% Midpoint of $97.4B or 5.0%
Estimated Reported Sales 3,6 	$96.9B - $97.9B
4.5% – 5.5% No FX impact
Adjusted Pre-Tax
Operating Margin4,5 	Approximately flat OPEX leverage offset
by inflationary pressures
Net Other Income4 	$1.9 - $2.1 billion 	Favorable employee benefit-related items
Net Interest Expense / (Income) 	$250 - $350 million Financing charges related to
the Abiomed Acquisition
Effective Tax Rate 4 	15.5% - 16.5% Based on current tax laws and
anticipated geographic mix
Adjusted EPS (Operational) 2,4 	$10.40 - $10.60
2.5% - 4.5% Midpoint of $10.50 or 3.5%
Adjusted EPS (Reported) 3,4 	$10.45 - $10.65
3.0% - 5.0%
+$0.05 or +0.5% FX impact
Midpoint of $10.55 or 4.0%

-- 30 of 40 --

2023 Sales Commentary
• 	Anticipate first half operational sales growth lower than the
second half driven by:
o 	Ongoing procedure recovery
o 	Q4 COVID-19 impacts in China continuing into 2023
o 	Ramp of new product launches
Pharmaceutical 	MedTech
31
January
Adjusted Operational Sales1,2,4 3.5% - 4.5%
Operational Sales2,4 $96.9B - $97.9B
4.5% – 5.5%
Estimated Reported Sales 3,4 $96.9B - $97.9B
4.5% – 5.5%
1 Non-GAAP measure; excludes acquisitions and divestitures 	3 Euro Average Rate: January 2023 = $1.08
2 Non-GAAP measure; excludes the impact of translational currency 	4 Excludes COVID-19 Vaccine
Note: Percentages may be rounded
• 	Anticipate first half operational sales growth lower than the
second half driven by:
o 	Impact from LOE products in Europe
o 	Ramp of new product launches
o 	Continued pricing pressures
• 	Pharmaceutical: Above market growth driven by key
brands and uptake of recently launched products partially
offset by LOEs
• 	MedTech: Competitive growth fueled by market recovery and
uptake of recently launched products
• 	Consumer Health: Growth in-line with the market and
strategic pricing to offset inflationary pressures
Adjusted Operational Sales Commentary by Segment
Phasing Considerations by Segment

-- 31 of 40 --

32
Anticipated 2023 Milestones Driving Long-Term
Value Creation
Pharmaceutical
Important launches, approvals
and data readouts
Consumer Health
Expect to complete the separation
MedTech
Key pipeline program updates

-- 32 of 40 --

Q&A
Joseph J. Wolk
Executive Vice President,
Chief Financial Officer
Jessica Moore
Vice President,
Investor Relations
Chairman of the Board and
Chief Executive Officer
Joaquin Duato

-- 33 of 40 --



-- 34 of 40 --

OTC
$6,031
Skin Health/Beauty
$4,352
Oral Care
$1,505
Baby Care
$1,461
Women's Health
$904
Wound Care/Other
$700
$14,953
(0.5)%, 3.6%
WW Sales $MM
■ Reported Growth 	■ Operational Growth 1
Consumer Health Highlights – Full Year 2022
Adjusted operational 2 growth driven by OTC
35
Key Drivers of Operational Performance1,3
OTC3
• 	Growth driven by increased Cough/Cold/Flu, adult and pediatric incidences, price
actions primarily in the U.S., and increased consumption due in China due to COVID-
19, partially offset by supply constraints
Skin
Health/
Beauty
• 	Decline driven by supply constraints in the U.S. partially offset by price actions and
strong new product performance in ASPAC and LATAM
Oral Care
• 	Decline driven by portfolio simplification in the U.S., competitive pressures in EMEA and
China, category decline and pricing pressures in EMEA, as well as suspension of
personal care sales in Russia and negative COVID-19 impacts in China
Baby Care • 	Decline driven by category deceleration and competitive pressures in the U.S.,
suspension of personal care sales in Russia, and weakness in India
Women’s
Health
• 	Growth driven by lapping prior year supply constraints in EMEA, strength in India, and
price actions in LATAM, partially offset by suspension of personal care sales in Russia
Wound
Care/Other
• 	Decline driven by lapping strong prior year consumption, competitive pressure in the
U.S., and decreased consumption in China
Adjusted Operational Sales2,3: WW 3.9%, U.S. 1.5%, Int’l 5.8%
Reported 3: 	WW (0.5)%, U.S. 1.3%, Int’l (1.9)%
Operational1,3: 	WW 3.6%, U.S. 1.3%, Int’l 5.3%
7.2%, 11.2%
(1.5)%, 7.0%
(5.3)%, (3.8)%
(6.7)%, (2.4)%
(8.5)%, (4.7)%
(4.2)%, (0.4)%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes; Note: Values may not add due to rounding
3

-- 35 of 40 --

1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
3 Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes; Note: Values may not add due to rounding
Key Drivers of Operational Performance1,3
Immunology
• 	Growth driven by continued strong uptake of STELARA in CD and UC
• 	Strength of TREMFYA in PsO and uptake in PsA
• 	REMICADE decline due to biosimilar competition
Infectious
Diseases 3
• 	Growth driven by the contribution of the COVID-19 Vaccine
• 	Partially offset by increased competition for PREZISTA/PREZCOBIX/REZOLSTA
and PREZISTA OUS LOE
Neuroscience 3
• 	Paliperidone long-acting injectables growth due to strength of INVEGA
SUSTENNA/XEPLION and INVEGA TRINZA/TREVICTA from new patient starts
and persistency, and the launch of INVEGA HAFYERA
Oncology
• 	DARZALEX increase driven by continued strong market growth and share gains in
all regions and uptake of the subcutaneous formulation
• 	Continued strong global launch uptake of ERLEADA
• 	IMBRUVICA decline primarily driven competitive pressures and market suppression
• 	ZYTIGA decline due to loss of exclusivity in EU
Cardiovascular/
Metabolism/
Other
(CVM/Other)3
• 	Decline driven by lower sales of PROCRIT/EPREX due to biosimilar competition
• 	INVOKANA/INVOKAMET decline due to continued share erosion
Pulmonary
Hypertension
(PH)
• 	Growth driven by sales of OPSUMIT and UPTRAVI due to continued share gains
and market growth, despite COVID-19 pressures
Adjusted Operational Sales2,3: WW 6.8%, U.S. 2.5%, Int’l 12.0%	Immunology
$16,935
Infectious Diseases
$5,449
Neuroscience
$6,893
Oncology
$15,983
CVM/Other
$3,887
PH
$3,417
$52,563
1.7%, 6.7%
WW Sales $MM
■ Reported Growth 	■ Operational Growth 1
Pharmaceutical Highlights – Full Year 2022
36
Reported 3: 	WW 1.7%, U.S. 2.3%, Int’l 1.0%
Operational1,3: 	WW 6.7%, U.S. 2.3%, Int’l 11.9%
(5.6)%, (4.0)%
(1.0)%, 3.0%
9.9%, 16.9%
(1.4)%, 3.4%
(6.5)%, 0.8%
1.1%, 4.8%
11 th consecutive year of above-market performance driven by double-digit growth in key products
3
3
3

-- 36 of 40 --

Orthopaedics
$8,587
Surgery
$9,690
Vision
$4,849
Interventional
Solutions
$4,300
$27,427
1.4%, 6.2%
WW Sales $MM
■ Reported Growth 	■ Operational Growth 1
MedTech Highlights – Full Year 2022
Growth primarily driven by market recovery, commercial initiatives and innovation
37
Reported: 	WW 1.4%, U.S. 5.4%, Int’l (2.3)%
Operational1: 	WW 6.2%, U.S. 5.4%, Int’l 6.9%
Key Drivers of Operational Performance1
Interventional
Solutions
• 	Electrophysiology: Market recovery, success of new products (VIZIGO and CARTO V7), and
commercial strategies continuing to enhance global leadership
Orthopaedics
• 	Hips: Growth reflects market recovery combined with continued strength of our portfolio including
ACTIS Stem and pull through from enabling technologies – KINCISE & VELYS Hip Navigation,
partially offset by volume-based procurement in China and OUS tender timing
• 	Trauma: Growth reflects global market recovery and uptake of new products including Advanced
Nailing Systems and VA Clavicle
• 	Knees: Growth primarily driven by procedure recovery, strength of the ATTUNE portfolio, and pull
through related to the VELYS Robotic assisted solution, partially offset by volume-based
procurement in China and OUS tender timing
• 	Spine, Sports & Other: Growth driven primarily by market recovery and benefit from new products
(VELYS Digital Solutions, INHANCE, SYMPHONY), partially offset by competitive pressures in
Spine and impacts of volume-based procurement
• 	Spine: WW: ~ -4%, U.S.: ~ -5%, OUS: ~ -1%
Surgery
• 	Advanced:
• 	Endocutters: ~ +3% Driven by market recovery, new products (ECHELON Staple Line
Reinforcement), and a reclass from General Surgery offsetting competitive pressure in the U.S.
• 	Biosurgery: ~ +5% Market recovery and success of newer products (VISTASEAL and
SURGICEL POWDER), partially offset by strong market demand in the prior year for infection
prevention products
• 	Energy: ~ +3% Primarily due to market recovery, benefits from new products (ENSEAL &
HARMONIC), and competitive supply challenges
• 	General: Growth primarily driven by market recovery and continued strength of the Suture portfolio
Vision
• 	Contact Lenses/Other: Growth driven primarily by market recovery and benefits from new
products (ACUVUE OASYS MAX and ACUVUE OASYS Multifocal)
• 	Surgical: Growth primarily due to market recovery and benefits from uptake of recently launched
products (TECNIS EYHANCE and TECNIS SYNERGY), partially offset by higher prior year U.S.
Refractory market
Adjusted Operational Sales2: WW 6.1%, U.S. 5.0%, Int’l 7.0%
8.3%, 13.7%
3.4%, 9.5%
0.0%, 3.7%
(1.2)%, 3.8%
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules in the Investors section of the company's website
2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules in the Investors section of the company's website
Note: Values may not add due to rounding; The MedTech segment was previously referred to as the Medical Devices segment

-- 37 of 40 --

2022 	2021 	%
Increase
(Decrease)	Amount 	% to Sales 	Amount 	% to Sales
Sales to customers 	$94,943 	100.0 	$93,775 	100.0 	1.3
Cost of products sold 	31,089 	32.7 	29,855 	31.8 	4.1
Gross Profit 	63,854 	67.3 	63,920 	68.2 	(0.1)
Selling, marketing and administrative expenses 	24,765 	26.1 	24,659 	26.3 	0.4
Research and development expense 	14,603 	15.4 	14,714 	15.7 	(0.8)
In-process research and development 	783 	0.8 	900 	1.0
Interest (income) expense, net 	(214) 	(0.2) 	130 	0.1
Other (income) expense, net 	1,871 	2.0 	489 	0.5
Restructuring 	321 	0.3 	252 	0.3
Earnings before provision for taxes on income 	21,725 	22.9 	22,776 	24.3 	(4.6)
Provision for taxes on income 	3,784 	4.0 	1,898 	2.0 	99.4
Net Earnings 	$17,941 	18.9 	$20,878 	22.3 	(14.1)
-
Net earnings per share (Diluted) 	$6.73 	$7.81 	(13.8)
Average shares outstanding (Diluted) 	2,663.9 	2,674.0
Effective tax rate 	17.4% 	8.3%
.
Adjusted earnings before provision for taxes and net earnings1
Earnings before provision for taxes on income 	$31,880 	33.6 	$30,464 	32.5 	4.6
Net earnings 	$27,038 	28.5 	$26,195 	27.9 	3.2
Net earnings per share (Diluted) 	$10.15 	$9.80 	3.6
Effective tax rate 	15.2% 	14.0%
Condensed Consolidated Statement of Earnings
1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules in the Investors section of the company's website 	38
Full Year 2022
(Unaudited; Dollar and Shares in Millions Except Per Share Figures)

-- 38 of 40 --

Adjusted Income Before Tax by Segment1
Full Year 2022
39
Pharmaceutical
MedTech
Consumer Health
Expenses Not Allocated to Segments
FY 2022 	FY 2021
Pharmaceutical 3 41.5% 	40.4%
MedTech 	26.1% 	25.7%
Consumer Health 3 23.6% 	24.5%
Total 	33.6% 	32.5%
% to Sales
2022 	2021
($0.6) 	($1.1)
$30.5B
$20.9
$7.0
$3.7
$31.9B
$21.8
$7.2
$3.5
2
1 	Non-GAAP measure; excludes amortization expense and special items; see reconciliation schedules in the Investors section of the company's website
2 	Estimated as of 1/24/2023
3 	Certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes

-- 39 of 40 --

40

-- 40 of 40 --